Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients – the study design of the LIBERAL-Trial
Authors:
- LIBERAL Collaboration GroupLGLIBERAL Collaboration Group
- Patrick MeybohmPMPatrick Meybohm
- Simone LindauSLSimone Lindau
- Sascha TreskatschSTSascha Treskatsch
- Roland FrancisRFRoland Francis
- Claudia SpiesCSClaudia Spies
- Markus VeltenMarkus Velten
- Maria WittmannMaria Wittmann
- Christian StoppeCSChristian Stoppe
- Ana KowarkAKAna Kowark
- Mark CoburnMCMark Coburn
Open Access
- 4 February 2019
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-10
Abstract
Perioperative anaemia leads to impaired oxygen supply with a risk of vital organ ischaemia. In healthy and fit individuals, anaemia can be compensated by several mechanisms. Elderly patients, however, have less compensatory mechanisms because of multiple co-morbidities and age-related decline of functional reserves. The purpose of the study is to evaluate whether elderly surgical patients may benefit from a liberal red blood cell (RBC) transfusion strategy compared to a restrictive transfusion strategy. The LIBERAL Trial is a prospective, randomized, multicentre, controlled clinical phase IV trial randomising 2470 elderly (≥ 70 years) patients undergoing intermediate- or high-risk non-cardiac surgery. Registered patients will be randomised only if Haemoglobin (Hb) reaches ≤9 g/dl during surgery or within 3 days after surgery either to the LIBERAL group (transfusion of a single RBC unit when Hb ≤ 9 g/dl with a target range for the post-transfusion Hb level of 9–10.5 g/dl) or the RESTRICTIVE group (transfusion of a single RBC unit when Hb ≤ 7.5 g/dl with a target range for the post-transfusion Hb level of 7.5–9 g/dl). The intervention per patient will be followed until hospital discharge or up to 30 days after surgery, whichever occurs first. The primary efficacy outcome is defined as a composite of all-cause mortality, acute myocardial infarction, acute ischaemic stroke, acute kidney injury (stage III), acute mesenteric ischaemia and acute peripheral vascular ischaemia within 90 days after surgery. Infections requiring iv antibiotics with re-hospitalisation are assessed as important secondary endpoint. The primary endpoint will be analysed by logistic regression adjusting for age, cancer surgery (y/n), type of surgery (intermediate- or high-risk), and incorporating centres as random effect. The LIBERAL-Trial will evaluate whether a liberal transfusion strategy reduces the occurrence of major adverse events after non-cardiac surgery in the geriatric population compared to a restrictive strategy within 90 days after surgery. ClinicalTrials.gov (identifier: NCT03369210 ).Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (ME 3559/3-1)
This publication has 31 references indexed in Scilit:
- Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012Intensive Care Medicine, 2013
- Transfusion Strategies for Acute Upper Gastrointestinal BleedingNew England Journal of Medicine, 2013
- Diabetes in Older Adults: A Consensus ReportJournal of the American Geriatrics Society, 2012
- Variability in Blood and Blood Component Utilization as Assessed by an Anesthesia Information Management SystemAnesthesiology, 2012
- Liberal or Restrictive Transfusion in High-Risk Patients after Hip SurgeryNew England Journal of Medicine, 2011
- Implications of demographics on future blood supply: a population‐based cross‐sectional studyTransfusion, 2010
- Risk analysis and risk adapted on-site monitoring in noncommercial clinical trialsClinical Trials, 2009
- Responsiveness of the EuroQol (EQ-5D) and the Nottingham Health Profile (NHP) in elderly patients with femoral neck fracturesQuality of Life Research, 2006
- Frailty in Older Adults: Evidence for a PhenotypeThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2001
- EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 2001